Novartis, PTC Therapeutics

Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) on December 3 and set a price target of ...
In a case-based competition, participants will be able to solve real-life problems in collaboration with experts from ...
Novartis Bangladesh Limited (“NBL”) announced on Thursday that the agreement by Novartis AG to transfer its shares in NBL to ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...